Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
111, Inc. is a China-based digital healthcare company focused on the online distribution of pharmaceutical products and healthcare services. The company operates in the digital healthcare, online pharmacy, and healthcare supply chain services industries, providing both business-to-consumer (B2C) and business-to-business (B2B) solutions. Its core activities center on enabling patients, pharmacies, and healthcare providers to access prescription and over-the-counter medicines through integrated online platforms.
The company’s primary revenue drivers historically include online pharmaceutical retailing, wholesale pharmaceutical distribution, and value-added services such as SaaS tools for pharmacies. 111, Inc. is best known for operating 1 Drugstore (1药网), one of China’s early online pharmacy platforms, which supports direct-to-consumer sales and prescription fulfillment. Founded in 2010, the company evolved from an online pharmacy startup into a broader digital healthcare platform and completed an initial public offering on NASDAQ in 2018. Public disclosures indicate that the company has faced regulatory, pricing, and profitability pressures in recent years, with aspects of its public listing status changing after 2022; details vary across public sources.
Business Operations
111, Inc. organizes its business around integrated online and offline pharmaceutical distribution and digital enablement services. Its operations historically included B2C online pharmacy services, B2B pharmaceutical supply services, and digital solutions for pharmacies, generating revenue primarily from drug sales, service fees, and supply chain support. The company leverages proprietary technology platforms to manage prescriptions, logistics coordination, and pharmacy management.
Operations are primarily concentrated in mainland China, where the company works with pharmaceutical manufacturers, distributors, and retail pharmacies. 111, Inc. controls technology platforms supporting drug sourcing, compliance, and data analytics, while also maintaining relationships with third-party logistics providers rather than owning a nationwide delivery network outright. Public filings reference collaborations with regional pharmacies and healthcare partners, though specific long-term joint ventures or equity partnerships are not consistently detailed across sources.
Strategic Position & Investments
Strategically, 111, Inc. has positioned itself as an infrastructure provider within China’s regulated digital healthcare ecosystem, aiming to connect drug manufacturers, pharmacies, and patients more efficiently. Growth initiatives disclosed in prior filings emphasized expanding prescription drug coverage, improving pharmacy SaaS penetration, and enhancing operational efficiency to address margin pressures in pharmaceutical retail.
The company has historically invested in technology development rather than large-scale acquisitions, with 1 Drugstore (1药网) remaining its most significant operating subsidiary and brand. Public sources indicate involvement in emerging areas such as online prescription services and digital chronic disease management, although the scale and commercial impact of these initiatives are not consistently quantified. Data on recent acquisitions or material equity investments is inconclusive based on available public sources.
Geographic Footprint
111, Inc. is headquartered in Shanghai, China, and its operations are overwhelmingly focused on the Chinese mainland market. The company serves customers across multiple provinces through its online platforms, with geographic reach enabled by partnerships with regional pharmacies and distributors rather than direct ownership of nationwide physical infrastructure.
While the company has historically accessed international capital markets through its U.S. listing and engaged global investors, there is no verified evidence of significant operational presence outside China. Any international influence appears primarily financial rather than operational, and disclosures do not indicate material overseas subsidiaries or revenue contributions.
Leadership & Governance
111, Inc. was founded by Victor Liu (Liu Jun), who has played a central role in shaping its digital healthcare strategy and platform-focused business model. Leadership communications in public filings emphasize regulatory compliance, technology-driven efficiency, and long-term integration of online and offline healthcare services as core elements of the company’s governance philosophy.
Key executives disclosed in public filings include:
- Victor Liu (Liu Jun) – Founder, Chairman, and Chief Executive Officer
- Guangyu Liu – Chief Financial Officer
- Wei Zhang – Chief Operating Officer
Public information on board composition and recent executive changes is limited and, in some cases, inconsistent across sources; where discrepancies exist, data is inconclusive based on available public sources.